Cosmetic cross-reference

Nipradilol

CAS 81486-22-8

Nipradilol (CAS 81486-22-8) is a Phase 2 pharmaceutical compound with 0 bioactivity targets and 2 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
2
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Nipradilol
CAS Number
81486-22-8
UNII
FVM336I71Y
InChIKey
OMCPLEZZPVJJIS-UHFFFAOYSA-N
ChEMBL ID
CHEMBL155622
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 2
Mid-stage clinical development phase from the compound identifier source.
ChEMBL CHEMBL155622 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Nipradilol used for in pharmaceutical contexts?

Nipradilol (CAS 81486-22-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Nipradilol?

Nipradilol has 2 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Glaucoma, Spinal osteoarthritis. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Nipradilol also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for NIPRADILOL with EU status "permitted".

What clinical phase is Nipradilol in?

Nipradilol is rendered with ChEMBL max phase 2.